Superworth

Equillium price to sales ratio EQ

Market value divided by revenue over the last twelve months, since 2024.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
0.4×
Aug 2025
Peer median
1.4×

Equillium's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2025, at 0.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
20250.4×0.3×0.7×
20240.5×0.5×2.3×

Against its peers

Companies in Drug Manufacturers - General nearest Equillium's size, closest first, today.

CompanyPrice to sales ratio
EQEquilliumn/m
LFVNLifevantage0.4×
SPROSpero Therapeutics1.4×
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products0.4×
ARVNArvinas1.5×
PBYIPuma Biotechnology2.5×
IRWDIronwood Pharmaceuticals1.5×
ZVRAZevra Therapeutics4.3×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical0.9×
Peer median1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Equillium

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.